Against a backdrop of rapid transformation in the healthcare sector, cell therapies are emerging as a revolutionary technology. Combining a history of continuous innovation, cutting-edge biotechnological advances and global industrial strategies, these approaches promise to rethink the treatment of diseases that have hitherto been difficult to cure. This article provides an accessible overview of the definition and historical development of cell therapies, recent innovations, their concrete clinical applications, and the economic, regulatory and industrial challenges that make them the future of the pharmaceutical sector.
What is cell therapy?
Cellular therapies involve using living cells to prevent, treat or cure diseases by restoring or modifying defective physiological functions.
A historical perspective :
The first approaches date back to the 1960s with bone marrow transplants, paving the way for stem cell treatments(1). Over the decades, advances in cell culture techniques and the boom in genetic engineering have enabled these strategies to be refined - from therapeutic stem cells to genome-editing approaches - and increasingly targeted treatments to be developed.
The current main categories include :
- Therapeutic stem cells(2) - offering the prospect of tissue regeneration thanks to their ability to differentiate.
- Modified cell therapies - such as CAR-T(3) cells, which redirect the immune system towards cancer cells, and other complementary immunotherapeutic approaches.
- Off-the-shelf cells(4) - derived from donors and enabling standardised production and wider deployment.
This historical development underlines how far we have come and the growing importance of cell therapies in modern medicine.
Recent biotechnological advances
The growth of cellular therapies is based on several major innovations which are accelerating their development:
- Genetic modification and genome editing
Technologies such as CRISPR-Cas9(5) enable precise manipulation of the genome, improving the safety and efficacy of modified cells for personalised clinical applications.
- Immunotherapy and complementary approaches
In addition to CAR-Ts, immunotherapy(6) includes strategies such as« adoptive cell transfer(7) and the use of immune checkpoint inhibitors(8), which boost the anti-tumour response and pave the way for combined treatments.
- Exosomes(9) and extracellular vesicles
The latest research is focusing on exosomes, the small vesicles secreted by cells, which can be used as vectors to deliver therapeutic signals and modulate the cellular microenvironment, offering a new dimension to regenerative approaches.
- Large-scale production platforms
Advances in automation and bio-production now make it possible to grow and modify cells in sufficient quantities to meet global demand, making these treatments economically viable.
Clinical applications: diseases that can be treated with cell therapies
Cell therapies offer new possibilities for treating a wide range of diseases. Some approaches have already been approved by the health authorities, while others are undergoing trials to verify their safety and efficacy.
- Cancers
Treatments such as CAR-T therapies (examples: Kymriah, Yescarta and Breyanzi) have shown good results in treating certain blood cancers, such as leukaemia and lymphoma. For solid cancers (those that develop in other organs), late-stage studies (phase II/III) are underway to find the best method of use.
- Rare and genetic diseases
Certain rare diseases that are often difficult to treat using traditional methods - for example, metabolic disorders such as hypoparathyroidism(10) - could benefit from treatments based on stem cells.
- Autoimmune diseases
Research is exploring the use of cells to help the immune system function better in diseases such as lupus(11) or rheumatoid arthritis(12), offering an alternative to current treatments that weaken the entire immune system.
- Heart problems and neurodegenerative diseases
Clinical trials are also testing the use of cell therapies to repair damaged tissue after a heart attack or to support recovery in neurodegenerative diseases such as Parkinson(13) and Alzheimer(14).
These ongoing studies and trials show that cell therapies are making real progress towards practical applications to improve patient health.
Industrial examples and global dimension
Faced with these innovations, many industrial players are consolidating their position through strategic investments and international partnerships:
- AstraZeneca
Committed to a strategy of acquisitions and partnerships, AstraZeneca continues to invest in innovative cell therapy platforms to treat rare diseases, cancers and other complex pathologies. - Bristol Myers Squibb and Kite Pharma
With products such as Breyanzi and Yescarta, these players dominate the North American market for CAR-T therapies, while continuing to develop new immunotherapeutic approaches. - European and Asian players
Companies such as Celyad in Belgium, as well as various biotechnology clusters(15) in Germany (BioRN, Munich Biotech Cluster), France (Paris-Saclay, Lyonbiopôle), Korea (Daedeok Innopolis) and Japan (Osaka Bio Valley, Tsukuba Science City), illustrate the global boom in cellular therapies, encouraging collaboration and innovation beyond traditional borders.
Economic outlook and challenges facing the sector
The global market for cell therapies is expected to reach between $15 and $20 billion by 2030, driven by growing demand for personalised treatments and considerable investment in R&D. Among the emerging business models, pay-for-performance(16) particularly well suited to single-use cell therapies, enabling the cost of treatment to be aligned with its actual clinical benefits.
However, a number of challenges remain:
- Access to reimbursement and market distribution
Reimbursement mechanisms remain a major obstacle, necessitating a review of healthcare policies to incorporate these costly treatments.
- Specific regulatory issues
Standardising production processes, guaranteeing the safety of living products and adapting regulatory frameworks to innovative approaches represent major challenges for health authorities.
- Pressure on traditional business models
The introduction of models such as pay-for-performance requires close collaboration between industry, regulators and insurers to ensure that therapeutic innovations are fairly valued.
In conclusion, cell therapies represent much more than a scientific breakthrough: they are revolutionising medicine by offering personalised treatments and opening up new therapeutic perspectives. On the strength of a rich history and major technological innovations - from genome editing to exosomes - these approaches are making rapid progress thanks to numerous late-stage clinical trials. At the same time, the emergence of innovative business models and the consideration of specific regulatory issues are positioning these technologies at the heart of the future strategies of industrial players. For investors and decision-makers, supporting this dynamic is essential if we are to meet tomorrow's health challenges while stimulating sustainable economic growth.
Definitions :
(1) Stem cells : "Stem cells are undifferentiated cells capable of self-renewal and differentiation to give rise to any of the body's specialised cells (blood cells, muscle cells, neurons, etc.)". To find out more, click here.
(2) Therapeutic stem cells : "Cell therapy involves transplanting cells to restore the function of a tissue or organ. The aim is to provide lasting treatment for the patient through a single injection of therapeutic cells. These cells are obtained from stem cells from the patient himself or from a donor". To find out more, click here.
(3) CAR-T cells : "CAR-T cells are T lymphocytes genetically modified to recognise and then eliminate cancer cells. They are the basis of a completely new approach to cancer treatment, which involves taking a patient's immune cells (in this case, T lymphocytes), genetically modifying them and reinjecting them into the patient". To find out more, click here.
(4) Off-the-shelf cells : "Immediately available and manageable cells”
(5) CRISPR-Cas9 "The CRISPR/Cas9 system is a new, simple, rapid and effective system for cutting DNA at a precise point in the genome, in any cell. It consists of a 'guide RNA', which targets a particular DNA sequence, combined with the Cas9 enzyme, which cuts the DNA like molecular scissors". To find out more, click here.
(6) Immunotherapy : This "therapeutic approach consists of activating the immune system of the patient to help it recognise cancer cells and destroy them". To find out more, click here.
(7) «Adoptive cell transfer "A type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer". To find out more, click here.
(8) Immune checkpoint inhibitors : "Checkpoints are proteins that prevent our immune system from destroying cancer cells. Checkpoint inhibitor drugs block these proteins, so that the immune system is still able to attack and destroy cancer cells". To find out more, click here.
(9) Exosomes : "Extracellular vesicles 50 to 150 nm in diameter formed inside cells from multivesicular bodies and secreted into the extracellular environment to communicate with a target cell". To find out more, click here.
(10) Hypoparathyroidism : "Hypoparathyroidism is a pathological condition caused by insufficient parathyroid hormone (PTH). This hormone is produced by the four parathyroid glands (of which there may be up to eight) generally located behind the gland thyroid in the neck". To find out more, click here.
(11) Lupus : "Systemic lupus erythematosus, also known as systemic lupus erythematosus or systemic lupus, is a chronic autoimmune disease. It is manifested by variable symptoms affecting various organs (skin, joints, etc.) Characteristic biological abnormalities are present". To find out more, click here.
(12) Rheumatoid arthritis : "Severe inflammatory disease affecting the joints”. To find out more, click here.
(13) Parkinson : "Parkinson's disease is a progressive neurodegenerative disorder characterised by the destruction of certain neurons in the brain and the accumulation of protein clusters that are toxic to nerve cells". To find out more, click here.
(14) Alzheimer : "Alzheimer's disease results from a slow degeneration of neurons, beginning in the hippocampus (a brain structure essential for memory) and then spreading to the rest of the brain. It is characterised by problems with recent memory, executive functions and orientation in time and space. Patients gradually lose their cognitive faculties and their autonomy". To find out more, click here.
(15) Biotechnology clusters : "Concentrations of biotechnology companies, research institutions, universities and related infrastructure in specific geographical areas". To find out more, click here.
(16) Pay-for-performance : “Financial or material transfers conditioned to the implementation of measurable resources or the achievement of defined performance objectives”. To find out more, click here.
Sources
- Le Point – April 3rd, 2024 – "Cell therapies will be at the heart of the future of the pharmaceutical industry"
- Baptiste 's Cochard thesis – November 22nd, 2023 - "Treatment with CAR-T cells: the place and prospects of this cell therapy in the management of diffuse large b-cell lymphoma"
• European Medicines Agency Information on advanced therapies
• Nature Reviews Drug Discovery – Review of therapeutic innovations
• Grand View Research – Analysis of the cell therapy market
• Fierce Biotech – News and analysis on pharmaceutical innovation
English (UK) 
Français